What are the key facts & figures for the UAE Obesity Drug Market?
Market Size
• 2023 Estimate: Around USD 120–150 million
• Projected CAGR (2023–2028): 8% to 12%
• 2028 Forecast: Could reach USD 220–250 million
Market Share by Drug Class
• GLP-1 Receptor Agonists: 70% of the market
• Other Anti-Obesity Medications (e.g., orlistat, phentermine): 30%Obesity Prevalence
• Adult Obesity Rate: 32% (among the highest in the GCC)
• Childhood Obesity: 17% (rising concern)
UAE Weight Loss Drug Market Size and Growth Forecast (2020–2030):
Key Insights:
• 2020 Market Size: $150 million
• 2025 Estimate: Around $230 million
• 2030 Projection: Over $345 million
• CAGR (2023–2030): 8.5%
Weight Loss Drug Market – by Drug Class
1. GLP-1 Receptor Agonists (e.g., Semaglutide, Liraglutide)
• Market Share: 60–70%
• Key Brands: Ozempic, Wegovy, Saxenda
• Growth Drivers:
o High efficacy in weight loss and diabetes management
o Strong demand from both medical and aesthetic consumers
o Increasing awareness and off-label use
• Challenges: High cost, limited availability at times
2. Lipase Inhibitors (e.g., Orlistat)
• Market Share: 10–15%
• Key Brands: Xenical, Alli
• Growth Drivers:
o Over-the-counter availability
o Long-standing presence in the market
• Challenges: Modest efficacy, gastrointestinal side effects
3. Appetite Suppressants / Sympathomimetics (e.g., Phentermine)
• Market Share: 5–10%
• Key Brands: Duromine, Adipex
• Growth Drivers:
o Short-term weight loss effectiveness
• Challenges: Regulatory restrictions, potential for abuse
4. Combination Therapies (e.g., Bupropion/Naltrexone)
• Market Share: 5%
• Key Brands: Contrave
• Growth Drivers:
o Targeting multiple mechanisms of weight control
• Challenges: Limited awareness and availability in the UAE
5. Herbal & Alternative Products
• Market Share: 5–10%
• Growth Drivers:
o Popularity in wellness and natural health circles
• Challenges: Lack of clinical evidence, regulatory scrutiny